SPRY (ARS Pharmaceuticals) Current Accrued Expense: $43.56 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPRY ARS Pharmaceuticals Inc SPRY
28 GF Score
Price $6.06
! 5 Warning Signs
View Full Analysis

What is ARS Pharmaceuticals Current Accrued Expense?

ARS Pharmaceuticals SPRY +1.51% 28 Current Accrued Expense is $43.56 Mil as of Mar. 2026. GuruFocus rates SPRY with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

ARS Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2026 was $43.56 Mil.

ARS Pharmaceuticals's quarterly Current Accrued Expense declined from Sep. 2025 ($35.94 Mil) to Dec. 2025 ($32.22 Mil) but then increased from Dec. 2025 ($32.22 Mil) to Mar. 2026 ($43.56 Mil).

ARS Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($1.08 Mil) to Dec. 2024 ($12.97 Mil) and increased from Dec. 2024 ($12.97 Mil) to Dec. 2025 ($32.22 Mil).

ARS Pharmaceuticals Current Accrued Expense Related Terms

ARS Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for ARS Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARS Pharmaceuticals Current Accrued Expense Chart

ARS Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 0.66 2.65 1.08 12.97 32.22

ARS Pharmaceuticals Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.18 24.40 35.94 32.22 43.56
SPRY
28GF Score
ARS Pharmaceuticals Inc SPRY
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ARS Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $43.56 Mil mean?
ARS Pharmaceuticals (SPRY) has a Current Accrued Expense of $43.56 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on ARS Pharmaceuticals and its competitors.
Is ARS Pharmaceuticals' Current Accrued Expense too high?
ARS Pharmaceuticals' current Current Accrued Expense is $43.56 Mil. Overall, ARS Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' Current Accrued Expense compare to ALLO and CBIO?
ARS Pharmaceuticals' Current Accrued Expense of $43.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on ARS Pharmaceuticals and its competitors. ARS Pharmaceuticals's current Current Accrued Expense is $43.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current Current Accrued Expense of $43.56 Mil. The current Current Accrued Expense is $43.56 Mil. ARS Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current Current Accrued Expense is $43.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ARS Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
28GF Score

Get the complete analysis for SPRY

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.06
Price